Study to explore heterologous regimen of COVID-19 vaccines from different manufacturers in adolescents 12-16 years of age
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
The batch will be distributed in India through a partner of RDIF and Panacea Biotec - Dr. Reddy's Laboratories
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik
This is the first of its kind vaccine for Covid 19 to get the go-ahead
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
AstraZeneca, Sinopharm and Moderna were part of the study
The first batch will be shipped to the Gamaleya Center for the quality control
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
Subscribe To Our Newsletter & Stay Updated
